{
    "root": "3fa2b889-ff04-4db1-b2c8-c0238efe240b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Revatio",
    "value": "20241218",
    "ingredients": [
        {
            "name": "SILDENAFIL CITRATE",
            "code": "BW9B0ZE037",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_58987"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "DEXTROSE, UNSPECIFIED FORM",
            "code": "IY9XDZ35W2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09341"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32159"
        },
        {
            "name": "XANTHAN GUM",
            "code": "TTV12P4NEE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_189560"
        }
    ],
    "indications": {
        "text": "adults revatio indicated treatment pulmonary arterial hypertension ( pah ) ( world health organization [ ] group ) adults improve exercise ability delay worsening [ ( 14 ) ] . pediatric patients ( 1 17 years old ) revatio indicated pediatric patients 1 17 years old treatment pulmonary arterial hypertension ( pah ) ( group ) improve exercise ability , pediatric patients young perform standardized exercise testing , pulmonary hemodynamics thought underlie improvements exercise [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 adults : 20 mg orally three times day . dose may increased based symptoms tolerability . ( 2.1 ) \u2022 pediatric patients ( 2.2 ) \u2264 20 kg : 10 mg three times day 20 kg 45 kg : 20 mg three times day > 45 kg : 20 mg three times day . dose may increased based symptoms tolerability . \u2022 injection ( adults ) : 10 mg three times day administered intravenous bolus injection . ( 2.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "revatio tablets supplied white off-white , film-coated , round tablets containing sildenafil citrate equivalent nominally indicated amount sildenafil follows : revatio tablets package configuration strength ndc engraving tablet bottle 90 tablets 20 mg 58151-402-77 \u201c rvt 20 \u201d one side \u201c vle \u201d side recommended storage revatio tablets : store controlled room temperature 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . revatio injection supplied clear , colorless , sterile , ready solution containing 10 mg sildenafil/12.5 ml ( 0.8 mg/ml ) presented single-dose glass vial . revatio injection package configuration strength ndc vial individually packaged carton 10 mg/12.5 ml ( 0.8 mg/ml ) 58151-395-31 recommended storage revatio injection : store controlled room temperature 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . discard unused portion . revatio powder oral suspension supplied amber glass bottles . bottle contains white slight pink powder containing 1.57 g sildenafil citrate ( equivalent 1.12 g sildenafil ) . following reconstitution , total volume oral suspension 112 ml ( 10 mg sildenafil/ml ) . 2 ml oral dosing syringe ( 1 ml 2 ml dose markings ) press-in bottle adaptor also provided . revatio powder oral suspension package configuration strength ndc powder oral suspension - bottle 10 mg/ml ( reconstituted ) 58151-385-35 recommended storage revatio oral suspension : store 30\u00b0c ( 86\u00b0f ) original package order protect moisture . recommended storage reconstituted oral suspension : store 30\u00b0c ( 86\u00b0f ) refrigerator 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) . freeze . shelf-life reconstituted oral suspension 60 days . remaining oral suspension discarded 60 days reconstitution .",
    "adverseReactions": "revatio contraindicated patients : \u2022concomitant organic nitrates form , either regularly intermittently , greater risk hypotension [ ( 5.1 ) ] . \u2022concomitant riociguat , guanylate cyclase stimulator . phosphodiesterase-5 ( pde-5 ) inhibitors , including sildenafil , may potentiate hypotensive effects riociguat . \u2022known hypersensitivity sildenafil component tablet , injection , oral suspension . hypersensitivity , including anaphylactic reaction , anaphylactic shock anaphylactoid reaction , reported association sildenafil .",
    "indications_original": "Adults\n                  \n                  REVATIO is indicated for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group I) in adults to improve exercise ability and delay clinical worsening [see Clinical Studies (14)]. \n                  \n                     Pediatric Patients (1 to 17 Years Old)\n                  \n                  REVATIO is indicated in pediatric patients 1 to 17 years old for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise [see Clinical Studies (14)].",
    "contraindications_original": "\u2022 Adults: 20 mg orally three times a day. Dose may be increased based on symptoms and tolerability. ( 2.1 ) \u2022 Pediatric patients ( 2.2 ) o \u2264 20 kg: 10 mg three times a day o 20 kg to 45 kg: 20 mg three times a day o > 45 kg: 20 mg three times a day. Dose may be increased based on symptoms and tolerability. \u2022 Injection (Adults): 10 mg three times a day administered as an intravenous bolus injection. ( 2.1 )",
    "warningsAndPrecautions_original": "REVATIO tablets are supplied as white to off-white, film-coated, round tablets containing sildenafil citrate equivalent to the nominally indicated amount of sildenafil as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              REVATIO Tablets\n                           \n                        \n                        \n                           \n                              Package Configuration\n                           \n                           \n                              Strength\n                           \n                           \n                              NDC\n                           \n                           \n                              Engraving on Tablet\n                           \n                        \n                        \n                           \n                              Bottle of 90 Tablets\n                           \n                           \n                              20\u00a0mg\n                           \n                           \n                              58151-402-77\n                           \n                           \n                              \u201cRVT 20\u201d on one side and \u201cVLE\u201d on the other side\n                           \n                        \n                     \n                  \n                  Recommended Storage for REVATIO Tablets: Store at controlled room temperature 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature].\n                  REVATIO injection is supplied as a clear, colorless, sterile, ready to use solution containing 10 mg sildenafil/12.5 mL (0.8 mg/mL) presented in a single-dose glass vial.\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              REVATIO Injection\n                           \n                        \n                        \n                           \n                              Package Configuration\n                           \n                           \n                              Strength \n                           \n                           \n                              NDC\n                           \n                        \n                        \n                           \n                              Vial individually packaged in a carton\n                           \n                           \n                              10 mg/12.5 mL (0.8 mg/mL)\n                           \n                           \n                              58151-395-31\n                           \n                        \n                     \n                  \n                  Recommended Storage for REVATIO Injection: Store at controlled room temperature 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Discard unused portion.\n                  REVATIO powder for oral suspension is supplied in amber glass bottles. Each bottle contains white to slight pink powder containing 1.57 g of sildenafil citrate (equivalent to 1.12 g sildenafil). Following reconstitution, the total volume of the oral suspension is 112 mL (10 mg sildenafil/mL). A 2 mL oral dosing syringe (with 1 mL and 2 mL dose markings) and a press-in bottle adaptor are also provided.\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              REVATIO Powder for Oral Suspension\n                           \n                        \n                        \n                           \n                              Package Configuration\n                           \n                           \n                              Strength \n                           \n                           \n                              NDC\n                           \n                        \n                        \n                           \n                              Powder for oral suspension - bottle\n                           \n                           \n                              10 mg/mL (when reconstituted)\n                           \n                           \n                              58151-385-35\n                           \n                        \n                     \n                  \n                  Recommended Storage for REVATIO for Oral Suspension: Store below 30\u00b0C (86\u00b0F) in the original package in order to protect from moisture.\n                  Recommended Storage for Reconstituted Oral Suspension: Store below 30\u00b0C (86\u00b0F) or in refrigerator at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F). Do not freeze. The shelf-life of the reconstituted oral suspension is 60 days. Any remaining oral suspension should be discarded 60 days after reconstitution.",
    "adverseReactions_original": "REVATIO is contraindicated in patients with:\n                  \n                     \n                        \u2022Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see \n                        \n                           Warnings and Precautions (5.1)\n                        \n                        ].\n                     \n                        \u2022Concomitant use of riociguat, a guanylate cyclase stimulator. Phosphodiesterase-5 (PDE-5) inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat.\n                     \n                        \u2022Known hypersensitivity to sildenafil or any component of the tablet, injection, or oral suspension. Hypersensitivity, including anaphylactic reaction, anaphylactic shock and anaphylactoid reaction, has been reported in association with the use of sildenafil.",
    "drug": [
        {
            "name": "Revatio",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_58987"
        }
    ]
}